Recro Pharma, Inc. (REPH)
REPHPrice: $2.09
Fair Value: 🔒
🔒score
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the for... more
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the developmen... more
Description
Shares
| Market Cap | $177.42M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Geraldine Henwood |
| IPO Date | 2014-03-07 | CAGR | — |
| Employees | 185 | Website | www.recrocdmo.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
REPH chart loading...
Fundamentals
Technicals
| Enterprise Value | $232.95M | P/E Ratio | -8.04 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1.23 | P/B Ratio | 1.79 |
| P/CF Ratio | -31.38 | P/FCF Ratio | -10.03 |
| EPS | $-0.26 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 4.9% | Gross Margin | 0.2% |
| Operating Margin | -0.02% | Profit Margin | -0.14% |
| ROE | -0.22% | ROA | -0.09% |
| ROCE | -0.02% | Current Ratio | 1.07 |
| Quick Ratio | 0.86 | Cash Ratio | 0.16 |
| Debt/Equity | 1.39 | Interest Coverage | -0.18 |
| Altman Z Score | -1.25 | Piotroski Score | 2 |